Type 2 Diabetes

Physical Activity and Type 2 Diabetes: When and How Much?

Both the timing and amount of physical activity are important in risk reduction and management of type 2 diabetes.

SUSTAIN-6: Cardiovascular Safety of Semaglutide in Type 2 Diabetes

Researchers found the cardiovascular safety of semaglutide was noninferior to placebo in high-risk patients with type 2 diabetes.

How Do We Use Technology for Diabetes Management?

Edward C. Chao, DO, highlights important considerations for developing technology for diabetes management.

Implementing Diabetes Self-Management Education in Type 2 Diabetes

Joan K. Bardsley, MBA, RN, CDE, describes a joint position statement regarding implementation of diabetes self-management education.

Role of the Gut Microbiome in Diabetes

Research shows that further understanding of the gut microbiome may improve diagnosis, prevention, and treatment of the disease earlier in life.

Preventing Diabetes and Complications: What Are the Challenges?

A change in how patients and physicians view diabetes may is necessary for preventing the disease and its complications.

LEADER: Liraglutide Decreased Rate of CV Events in High-Risk Type 2 Diabetes

Compared with placebo, liraglutide decreased the rate of cardiovascular events in high-risk patients with diabetes.

SGLT2 Inhibitors: A Class Effect?

Data on cardiovascular benefits as well as adverse effects have thrust this class of diabetes drugs into the spotlight.

Physical Activity Deficiency: A New Risk Factor for Type 2 Diabetes?

Sedentary behaviors may boost risk for type 2 diabetes by 22% and risk for metabolic syndrome by 39%.

AACE Issues Consensus Statement on Outpatient Glucose Monitoring in Diabetes

The new consensus statement reflects the advances made in glucose monitoring technology and offers guidance for clinicians.

AACE/ACE Updates Algorithm for Type 2 Diabetes Management

The American Association of Clinical Endocrinologists' updated algorithm for type 2 diabetes management addresses lifestyle modifications and obesity treatments.

Video

Latest Headlines

ADA: Clinical Benefit With Alirocumab in T2D Plus Statin Therapy

ADA: Clinical Benefit With Alirocumab in T2D Plus Statin Therapy

Researchers presented data from the ODYSSEY DM Insulin and Dyslipidemia trials at ADA 2017.

Semaglutide Improved Beta-Cell Function and Glycemic Control in Type 2 Diabetes

Semaglutide Improved Beta-Cell Function and Glycemic Control in Type 2 Diabetes

Semaglutide significantly increased insulin response and was well-tolerated in patients with type 2 diabetes.

Cardiometabolic Disease Staging Score Useful in Quantifying T2D Risk in Overweight, Obesity

Cardiometabolic Disease Staging Score Useful in Quantifying T2D Risk in Overweight, Obesity

Cardiometabolic Disease Staging scores can be used to quantify diabetes risk and assess efficacy of weight loss pharmacotherapy in obesity.

Blood Glucose Self-Monitoring in Type 2 Diabetes Does Not Benefit Glycemic Control

Blood Glucose Self-Monitoring in Type 2 Diabetes Does Not Benefit Glycemic Control

There were no significant differences in hemoglobin A1c across the 3 self-monitoring blood glucose groups.

Improving Glycemic Control in T2D With Text Message Intervention

Improving Glycemic Control in T2D With Text Message Intervention

Three-times daily text messages over a 6 month period were found to improve glycemic control vs usual care.

Major Cardiovascular Event Incidence in T2D: Degludec vs Glargine

Major Cardiovascular Event Incidence in T2D: Degludec vs Glargine

Degludec is noninferior to glargine in terms of incidence of major cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.

Pooled Analysis Demonstrates Safety, Tolerability of Empagliflozin

Pooled Analysis Demonstrates Safety, Tolerability of Empagliflozin

A pooled analysis examined the rates of amputation and fracture in patients with type 2 diabetes prescribed empagliflozin.

FDA: Application Submitted for CV Safety Data Review of Insulin Degludec

FDA: Application Submitted for CV Safety Data Review of Insulin Degludec

The FDA is poised to review data from the DEVOTE trial, examining the rates of major adverse cardiovascular events in insulin degludec vs insulin glargine.

Cruciferous Vegetables May Regulate Dysglcemia In Obesity With T2D

Cruciferous Vegetables May Regulate Dysglcemia In Obesity With T2D

Sulforaphane extract from cruciferous vegetables aids in dysglycemia regulation in patients with obesity and type 2 diabetes.

Extended-Release Naltrexone/Bupropion Efficacious for Weight Loss in Type 2 Diabetes

Extended-Release Naltrexone/Bupropion Efficacious for Weight Loss in Type 2 Diabetes

Two studies examined the effects of naltrexone/bupropion on weight loss, glycemic parameters, and cardiovascular risks in patients with type 2 diabetes.

Sign Up for Free e-Newsletters